Ra Pharmaceuticals Gets a Buy Rating from Jefferies

By Carrie Williams

Jefferies analyst Biren Amin reiterated a Buy rating on Ra Pharmaceuticals (NASDAQ: RARX) today and set a price target of $25. The company’s shares closed yesterday at $24.02.

According to TipRanks.com, Amin is a 3-star analyst with an average return of 2.7% and a 46.7% success rate. Amin covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Stemline Therapeutics Inc, and Lion Biotechnologies Inc.

Ra Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $28.

The company has a one year high of $27.84 and a one year low of $12.05. Currently, Ra Pharmaceuticals has an average volume of 91.51K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It provides pharmaceutical products for treatment of diseases of complement dysregulation. It utilizes small molecules and peptide to address pathological targets in the complement cascade. It develops a portfolio of drugs and partnerships focused on intracellular protein-protein interactions and other innovative approaches for addressing unmet medical needs. The company was founded by Doug A. Treco and James W. Broderick in 2008 and is headquartered in Cambridge, MA.